-
Signature
-
/s/ Andrew LaFrence, attorney-in-fact
-
Stock symbol
-
VYNT
-
Transactions as of
-
Mar 30, 2021
-
Transactions value $
-
$0
-
Form type
-
4/A - Amendment
-
Date filed
-
7/13/2021, 09:00 AM
-
Date Of Original Report
-
Apr 1, 2021
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
VYNT |
Common Stock, $0.0001 par value |
Other |
|
+598K |
|
|
598K |
Mar 30, 2021 |
Direct |
F1 |
transaction |
VYNT |
Common Stock, $0.0001 par value |
Other |
|
+64.9K |
|
|
64.9K |
Mar 30, 2021 |
By Trust |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
1. Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's Common Stock in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.